Annexon, Inc. $ANNX Holdings Lifted by Park Avenue Securities LLC

Park Avenue Securities LLC raised its position in Annexon, Inc. (NASDAQ:ANNXFree Report) by 36.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 113,068 shares of the company’s stock after purchasing an additional 30,000 shares during the quarter. Park Avenue Securities LLC owned about 0.10% of Annexon worth $271,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in ANNX. Alpine Global Management LLC acquired a new position in Annexon during the 1st quarter valued at about $49,000. Forefront Analytics LLC boosted its holdings in shares of Annexon by 74.0% in the first quarter. Forefront Analytics LLC now owns 28,591 shares of the company’s stock valued at $55,000 after acquiring an additional 12,158 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Annexon by 164.1% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,026 shares of the company’s stock valued at $66,000 after acquiring an additional 21,143 shares during the period. Hsbc Holdings PLC raised its holdings in Annexon by 19.9% during the first quarter. Hsbc Holdings PLC now owns 36,935 shares of the company’s stock worth $73,000 after purchasing an additional 6,136 shares in the last quarter. Finally, EntryPoint Capital LLC acquired a new stake in Annexon in the first quarter worth approximately $103,000.

Analyst Ratings Changes

ANNX has been the subject of a number of research reports. Zacks Research raised Annexon from a “strong sell” rating to a “hold” rating in a research note on Monday, August 18th. HC Wainwright reaffirmed a “buy” rating and set a $14.00 target price on shares of Annexon in a research note on Friday, August 15th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, Annexon has an average rating of “Moderate Buy” and an average price target of $12.50.

Read Our Latest Stock Analysis on Annexon

Annexon Trading Down 0.7%

ANNX stock opened at $3.03 on Thursday. Annexon, Inc. has a one year low of $1.28 and a one year high of $7.85. The firm has a 50-day moving average of $2.45 and a two-hundred day moving average of $2.25. The firm has a market capitalization of $332.97 million, a PE ratio of -2.35 and a beta of 1.36.

Annexon (NASDAQ:ANNXGet Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.02. On average, equities research analysts anticipate that Annexon, Inc. will post -0.96 earnings per share for the current year.

About Annexon

(Free Report)

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.

See Also

Want to see what other hedge funds are holding ANNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Annexon, Inc. (NASDAQ:ANNXFree Report).

Institutional Ownership by Quarter for Annexon (NASDAQ:ANNX)

Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.